

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	10/533,685 (U.S. National Phase of PCT/US2004/008323)
I.A. Filing Date	March 17, 2004
First Named Inventor	Shu MI
Art Unit	To Be Assigned 1656
Examiner Name	To Be Assigned Carlson
Attorney Docket Number	2159.0440003/EJH/J-H

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (If Known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/KCC/	US1	4,399,216	08-16-1983	Axel et al.	
	US2	4,510,245	04-09-1985	Cousens et al.	
	US3	4,634,665	01-06-1987	Axel et al.	
	US4	4,968,615	11-06-1990	Koszynowski et al..	
	US5	5,168,062	12-01-1992	Mark F. Stinski	
	US6	5,179,017	01-12-1993	Axel et al.	
	US7	5,252,714	10-12-1993	Harris et al.	
	US8	5,428,130	06-27-1995	Capon et al.	
	US9	5,565,335	10-15-1996	Capon et al.	
	US10	6,190,887 B1	02-20-2001	Boyce et al.	
	US11	6,338,953 B1	01-15-2002	Boyce et al.	
	US12	6,686,451 B1	02-03-2004	Desnoyers et al.	
	US13	6,974,689 B1	12-13-2005	Ashkenazi et al.	
	US14	2003/0195163	10-16-2003	Wu et al.	
	US15	2004/0067490 A1	04-08-2004	Zhong et al.	
	US16	2004/0253605 A1	12-16-2004	McCarthy et al.	
	US17	2005/0123990 A1	06-09-2005	Lai et al.	
	US18	2005/0215770 A1	09-29-2005	Bell et al.	
	US19	2005/0214288 A1	09-29-2005	Bell et al.	
	US20	2006/0009388 A1	01-12-2006	Mi et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ³ Kind Code ⁴ (If Known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	FP1	EP 0 154 316 B1	09-11-1985	Takeda Chemical Ind., Ltd.		
	FP2	EP 0 401 384 B1	03-13-1996	Kirin-Amgen, Inc.		
	FP3	WO 86/005807 A1	10-09-1986	Celltech Limited		
	FP4	EP 0 256 055 B1	08-28-1991	Celltech Limited		
	FP5	EP 0 323 997 B1	04-21-1993	Celltech Limited		
	FP6	EP 0 338 841 B1	04-18-1989	Celltech Limited		
	FP7	WO 2002/014368 A2	02-21-2002	Curagen Corporation.		
	FP8	WO 2002/029058 A2	04-11-2002	Curagen Corp.		
/KCC/	FP9	WO 2002/068579 A2	09-06-2002	PE Corporation (NY)		

Examiner Signature	/Karen Cochran Carlson/ (11/19/2008)	Date Considered	
--------------------	--------------------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of WIPO Standard ST.16 at www.wipo.int or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols, preceded by the serial number on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2. 571791_1.DOC

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	10/553,685 (U.S. National Phase of PCT/US2004/008323)
I.A. Filing Date	March 17, 2004
First Named Inventor	Shu MI
Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	2159.04440003/EJH/J-H

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)	MM-DD-YYYY		
/KCC/	US21	2002/0123057 A1	09-05-2002	Zauderer et al.	
	US22				
	US23				
	US24				
	US25				
	US26				
	US27				
	US28				
	US29				
	US30				
	US31				
	US32				
	US33				
	US34				
	US35				
	US36				
	US37				
	US38				
	US39				
	US40				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ¹ Number ² Kind Code ² (if known)	MM-DD-YYYY			
/KCC/	FP10	WO 2004/085648 A2	10-07-2004	Biogen IDEC MA Inc.		
	FP11	WO 2003/035833 A2	05-01-2003	EXELIXIS, Inc.		
	FP12	WO 2003/023008 A2	03-20-2003	Curagen Corporation		
	FP13	WO 2003/083047 A2	10-09-2003	EXELIXIS, Inc.		
	FP14	WO 2001/012662 A2	02-22-2001	Incyte Genomics, Inc.		
	FP15	WO 1999/006427 A1	02-11-1999	Millennium Biotherapeutics, Inc.		
	FP16	WO 2001/040466 A1	06-07-2001	Genentech, Inc.		
	FP17	WO 2005/079566 A2	09-01-2005	Lexicon Genetics Inc.		
	FP18	WO 1999/014328 A2	03-25-1999	Genentech, Inc.		

Examiner Signature	/Karen Cochran Carlson/(11/19/2008)	Date Considered	
--------------------	-------------------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2. 571791_1.DOC

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet

3

of

3

Complete if Known

Application Number	10/553,685 (U.S. National Phase of PCT/US2004/008323)
I.A. Filing Date	March 17, 2004
First Named Inventor	Shu MI
Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	2159.00440003/EJH/J-H

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	US41				
	US42				
	US43				
	US44				
	US45				
	US46				
	US47				
	US48				
	US49				
	US50				
	US51				
	US52				
	US53				
	US54				
	US55				
	US56				
	US57				
	US58				
	US59				
	US60				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
/KCC/	FP19	WO 2001/004311 A1	01-18-2001	Genentech, Inc.		
	FP20	WO 2000/015796 A2	03-23-2000	Genentech, Inc.		
	FP21	EP 1 574 520 A2	09-14-2005	Nuvolo, Inc.		
	FP22	WO 01/057262 A1	08-09-2001	HYSEQ, Inc.		
/KCC/	FP23	EP 1 074 617 A2	02-07-2001	Helix Research Institute		
	FP24					
	FP25					
	FP26					
	FP27					

Examiner Signature	/Karen Cochran Carlson/ (11/19/2008)	Date Considered	
--------------------	--------------------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Applications at uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2. 571791_1.DOC

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/553,685 (U.S. National Phase of PCT/US2004/008323)
				I.A. Filing Date	March 17, 2004
				First Named Inventor	Sha MI
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	1	of	4	Attorney Docket Number	2159.0440003/EJII/J-H

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published			T ²
/KCC/	NPL1	Rutishauser, U. <i>et al.</i> , "Cell Adhesion Molecules in Vertebrate Neural Development," <i>Physiol. Rev.</i> 68:819-857, American Physiological Society (1988)			
	NPL2	Brittis, P.A., <i>et al.</i> , "Nogo Domains and a Nogo Receptor: Implications for Axon Regeneration," <i>Neuron</i> 30:11-14 Cell Press (2001)			
	NPL3	Jones, L.L., <i>et al.</i> , "NG2 Is a Major Chondroitin Sulfate Proteoglycan Produced after Spinal Cord Injury and Is Expressed by Macrophages and Oligodendrocyte Progenitors," <i>J. Neurosci.</i> 22:2792-2803, Society for Neuroscience (2002)			
	NPL4	Grimpe, B., <i>et al.</i> , "The Critical Role of Basement Membrane-Independent Laminin $\gamma 1$ Chain During Axon Regeneration in the CNS," <i>J. Neurosci.</i> 22:3144-3160, Society for Neuroscience (2002)			
	NPL5	Chen, M.S., <i>et al.</i> , "Nogo-A is a Myelin-Associated Neurite Outgrowth Inhibitor and an Antigen for Monoclonal Antibody IN-1," <i>Nature</i> 403:434-439, Macmillan Magazines Ltd. (2000)			
	NPL6	Grandpré, T., <i>et al.</i> , "Identification of the Nogo Inhibitor of Axon Regeneration as a Reticulon Protein," <i>Nature</i> 403:439-444, Macmillan Magazines Ltd. (2000)			
	NPL7	McKerracher, L., <i>et al.</i> , "Identification of Myelin-Associated Glycoprotein as a Major Myelin-Derived Inhibitor of Neurite Growth," <i>Neuron</i> 13:805-811, Cell Press (1994)			
	NPL8	Mukhopadhyay, G., <i>et al.</i> , "A Novel Role for Myelin-Associated Glycoprotein as an Inhibitor of Axonal Regeneration," <i>Neuron</i> 13:757-767, Cell Press (1994)			
	NPL9	Mikol D.D. <i>et al.</i> , "A Phosphatidylinositol-Linked Peanut Agglutinin-Binding Glycoprotein in Central Nervous System Myelin and on Oligodendrocytes," <i>J. Cell. Biol.</i> 106:1273-1279, The Rockefeller University Press (1988)			
/KCC/	NPL10	Wang, K.C., <i>et al.</i> , "Oligodendrocyte-Myelin Glycoprotein is a Nogo Receptor Ligand That Inhibits Neurite Outgrowth," <i>Nature</i> 417:941-944, Nature Publishing Group (2002)			

Examiner Signature	/Karen Cochrane Carlson/ (11/19/2008)	Date Considered	
--------------------	---------------------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comment on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known																	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/553,685 (U.S. National Phase of PCT/US2004/008323)</td> </tr> <tr> <td>I.A. Filing Date</td> <td>March 17, 2004</td> </tr> <tr> <td>First Named Inventor</td> <td>Sha MI</td> </tr> <tr> <td>Art Unit</td> <td>To be assigned</td> </tr> <tr> <td>Examiner Name</td> <td>To be assigned</td> </tr> <tr> <td>Sheet</td> <td>2</td> <td>of</td> <td>4</td> <td>Attorney Docket Number</td> <td>2159.0440003/EJH/J-H</td> </tr> </table>		Application Number	10/553,685 (U.S. National Phase of PCT/US2004/008323)	I.A. Filing Date	March 17, 2004	First Named Inventor	Sha MI	Art Unit	To be assigned	Examiner Name	To be assigned	Sheet	2	of	4	Attorney Docket Number	2159.0440003/EJH/J-H
Application Number	10/553,685 (U.S. National Phase of PCT/US2004/008323)																				
I.A. Filing Date	March 17, 2004																				
First Named Inventor	Sha MI																				
Art Unit	To be assigned																				
Examiner Name	To be assigned																				
Sheet	2	of	4	Attorney Docket Number	2159.0440003/EJH/J-H																
NON PATENT LITERATURE DOCUMENTS																					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published			T ²																
/KCC	NPL11	Domeniconi M., et al., "Myelin-Associated Glycoprotein Interacts with the Nogo66 Receptor to Inhibit Neurite Outgrowth," <i>Neuron</i> 35:283-290, Cell Press (2002)																			
	NPL12	Fournier, A.E., et al., "Identification of a Receptor Mediating Nogo-66 Inhibition of Axonal Regeneration," <i>Nature</i> 409:341-346, Nature Publishing Group (2001)																			
	NPL13	Kasper, C., et al., "Structural Basis of Cell - Cell Adhesion by NCAM," <i>Nat. Struct. Biol.</i> 7:389-393, Nature America Inc. (2000)																			
	NPL14	Carim-Todd, L., et al., "LRRN6A/LERN1 (Leucine-Rich Repeat Neuronal Protein 1), a Novel Gene with Enriched Expression in Limbic System and Neocortex," <i>Eur. J. Neurosci.</i> 18:3167-3183, Federation of European Neuroscience Societies (2003)																			
	NPL15	Chen, Y., et al., "AMIGO and Friends: An Emerging Family of Brain-Enriched, Neuronal Growth Modulating, Type 1 Transmembrane Proteins with Leucine-Rich Repeats (LRR) and Cell Adhesion Molecule Motifs," <i>Brain Res. Rev.</i> 51:265-74, Elsevier (2006)																			
	NPL16	Huang, J., et al., "Glial Membranes at the Node of Ranvier Prevent Neurite Outgrowth," <i>Science</i> 310:1813-7 (2005)																			
	NPL17	Li, W., et al., "Neutralization of Myelin-Associated NOGO-A by a NOGO Receptor-FC Fusion Protein," <i>Society for Neuroscience Abstracts</i> ABS3332 (2002)																			
	NPL18	Mi, S., et al., "LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex," <i>Nat. Neurosci.</i> 7:221-8, Nature Publishing Group (2004)																			
	NPL19	Mi, S., et al., "A Novel CNS-Specific Protein Promotes Axonal Elongation by Modulating RHOA Signaling," <i>Society for Neuroscience Abstracts</i> , Abstract No. 891.5 (2003)																			
↓	NPL20	Mi, S., et al., "LINGO-1 Negatively Regulates Myelination by Oligodendrocytes," <i>Nat. Neurosci.</i> 8:745-51, Nature Publishing Group (2005)																			
Examiner Signature	/Karen Cochran Carlson/ (11/19/2008)		Date Considered																		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments or suggestions on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet

3

of

4

Complete if Known

Application Number	10/553,685 (U.S. National Phase of PCT/US2004/08323)
I.A. Filing Date	March 17, 2004
First Named Inventor	Sha MI
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	2159.0440003/EJH/J-H

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city or country where published	T ²
/KCC/	NPL21	Okafuji, T., et al., "Expression Pattern of LINGO-1 in the Developing Nervous System of the Chick Embryo," <i>Gene Expr. Patterns</i> 6:57-62, Elsevier (2005)	
	NPL22	Park, J.B., et al., A TNF Receptor Family Member, TROY, is a Coreceptor with Nogo Receptro in Mediating the Inhibitory Activity of Myelin Inhibitors," <i>Neuron</i> 3:345-51, Cell Press (2005)	
	NPL23	Shao, Z., et al., "TAJ/TROY, an Orphan TNF Receptor Family Member, Binds Nogo-66 Receptor 1 and Regulates Axonal Regeneration," <i>Neuron</i> 45:353-9, Cell Press (2005)	
	NPL24	Trifunovski, A. et al. "Neuronal activity-induced regulation of LINGO-1," <i>Neuroreport</i> 15:2397-2400 (2004)	
	NPL25	Yu, W., et al., "Segregation of Nogo66 Receptors into Lipid Rafts in Rat Brain and inhibition of Nogo66 signaling by cholesterol depletion," <i>FEBS Lett.</i> 577:87-92 (2004)	
	NPL26	NCBI Entrez, Accession No. BC011057, Strausberg, R.L., et al. (first available 07/30/2001; last updated 07/15/2006)	
	NPL27	NCBI Entrez, Accession No. BC068558, Strausberg, R.L., et al. (first available 04/06/2004; last updated 07/21/2005)	
	NPL28	NCBI Entrez, Accession No. NM_152570, Clark, H.F., et al. (first available 09/06/2002; last updated 12/25/2005)	
	NPL29	NCBI Entrez, Accession No. NM_032808, Carim-Todd, L., et al. (first available 05/31/2001; last updated 09/17/2006)	
V /KCC/	NPL30	NCBI Entrez, Accession No. DR000281, Birkett, C., et al. (first available 05/17/2005; last updated 05/17/2005)	

Examiner Signature	/Karen Cochrane Carlson/ (11/19/2008)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments or suggestions on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/553,685 (U.S. National Phase of PCT/US2004/008323)
				I.A. Filing Date	March 17, 2004
				First Named Inventor	Sha MI
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	4	of	4	Attorney Docket Number	2159.0440003/EJH/J-H

/KCC/	NPL31	NCBI Entrez, Accession No. AY324320, Carim-Todd, L., et al. (first available 05/04/2004; last updated 05/04/2004)
/KCC/	NPL32	NCBI Entrez, Accession No. AY324323, Carim-Todd, L., et al. (first available 05/04/2004; last updated 05/04/2004)

571837_1.DOC

Examiner Signature	/Karen Cochrane Carlson/ (11/19/2008)	Date Considered	
--------------------	---------------------------------------	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.